Guillain-Barré syndrome: A century of progress

Nature Reviews Neurology

Volumn 12, Issue 12, 2016, Pages 723-731

  Goodfellow, John A ^a   Willison, Hugh J ^b  

^a QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ECULIZUMAB; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN; PLACEBO; SWINE INFLUENZA VACCINE; GANGLIOSIDE;

AREFLEXIA; ATAXIA; AUTOPSY; AXONAL INJURY; BACTERIAL STRAIN; CAMPYLOBACTER JEJUNI; CLINICAL TRIAL (TOPIC); DEMYELINATING DISEASE; ELECTROPHYSIOLOGY; GLIA CELL; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; MOLECULAR MIMICRY; NERVE CELL MEMBRANE; NEUROMUSCULAR JUNCTION; NONHUMAN; OPHTHALMOPLEGIA; PATHOPHYSIOLOGY; PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SWINE INFLUENZA; ZIKA VIRUS; ANIMAL; AXON; HISTORY; IMMUNOLOGY; PATHOGENICITY; PATHOLOGY; PROCEDURES;

ANIMALS; AXONS; CAMPYLOBACTER JEJUNI; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTHERAPY;

EID: 84995791035     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2016.172     Document Type: Review

References (98)

1. Landry, O. Note sur la paralysie ascendante aiguë. Gaz. Hebd. Méd. Chir. 6, 472-474, 486-488 (in French) (1859).
2. Guillain, G., Barré, J. A. & Strohl, A. Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes. 1916. Ann. Med. Interne (Paris) 150, 24-32 (in French) (1999).
3. Pearce, J. M. Walter Essex Wynter, Quincke, and lumbar puncture. J. Neurol. Neurosurg. Psychiatry 57, 179 (1994).
4. Fokke, C. et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 137, 33-43 (2014).
5. Draganescu, S. & Claudian, J. Sur un cas de radiculo-névrite curable (syndrome de Guillain-Barré). Rev. Neurol. 2, 517-521 (in French) (1927).
6. Haymaker, W. E. & Kernohan, J. W. The Landry-Guillain-Barré syndrome; a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore) 28, 59-141 (1949).
7. Waksman, B. H. & Adams, R. D. Allergic neuritis: an experimental disease of rabbits induced by the injection of peripheral nervous tissue and adjuvants. J. Exp. Med. 102, 213-236 (1955).
8. Astrom, K. E. & Waksman, B. H. The passive transfer of experimental allergic encephalomyelitis and neuritis with living lymphoid cells. J. Pathol. Bacteriol. 83, 89-106 (1962).
9. Kadlubowski, M. & Hughes, R. A. Identification of the neuritogen for experimental allergic neuritis. Nature 277, 140-141 (1979).
10. Linington, C. et al. A permanent rat T cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. J. Immunol. 133, 1946-1950 (1984).
11. Yan, W. et al. Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis. J. Neuroimmunol. 277, 13-17 (2014).
12. Asbury, A. K., Arnason, B. G. & Adams, R. D. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 48, 173-215 (1969).
13. Wiśniewski, H., Terry, R. D., Whitaker, J. N., Cook, S. D. & Dowling, P. C. Landry-Guillain-Barré syndrome. A primary demyelinating disease. Arch. Neurol. 21, 269-276 (1969).
14. Prineas, J. W. Acute idiopathic polyneuritis. An electron microscope study. Lab. Invest. 26, 133-147 (1972).
15. Brechenmacher, C. et al. Guillain-Barré syndrome: an ultrastructural study of peripheral nerve in 65 patients. Clin. Neuropathol. 6, 19-24 (1987).
16. Fisher, M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N. Engl. J. Med. 255, 57-65 (1956).
17. Shahrizaila, N. & Yuki, N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J. Neurol. Neurosurg. Psychiatry 84, 576-583 (2013).
18. Schonberger, L. B. et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am. J. Epidemiol. 110, 105-123 (1979).
19. Kurland, L. T., Wiederholt, W. C., Kirkpatrick, J. W., Potter, H. G. & Armstrong, P. Swine influenza vaccine and Guillain-Barré syndrome. Epidemic or artifact? Arch. Neurol. 42, 1089-1090 (1985).
20. Langmuir, A. D., Bregman, D. J., Kurland, L. T., Nathanson, N. & Victor, M. An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines. Am. J. Epidemiol. 11 9, 841-879 (1984).
21. Lasky, T. et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N. Engl. J. Med. 339, 1797-1802 (1998).
22. Osler, L. D. & Sidell, A. D. The Guillain-Barre syndrome; the need for exact diagnostic criteria. N. Engl. J. Med. 262, 964-969 (1960).
23. [No authors listed.] Criteria for diagnosis of Guillain-Barré syndrome. Ann. Neurol. 3, 565-566 (1978).
24. Asbury, A. K. Diagnostic considerations in Guillain-Barré syndrome. Ann. Neurol. 9 (Suppl.), 1-5 (1981).
25. Asbury, A. K. & Cornblath, D. R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 27 (Suppl.), S21-S24 (1990).
26. Schengrund, C. L. Gangliosides: glycosphingolipids essential for normal neural development and function. Trends Biochem. Sci. 40, 397-406 (2015).
27. Dodge, J. C. et al. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA 11 2, 8100-8105 (2015).
28. Nagai, Y., Momoi, T., Saito, M., Mitsuzawa, E. & Ohtani, S. Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci. Lett. 2, 107-111 (1976).
29. Díez-Tejedor, E., Gutiérrez-Rivas, E. & Gil-Peralta, A. Gangliosides and Guillain-Barré syndrome: the Spanish data. Neuroepidemiology 12, 251-256 (1993).
30. Matias-Guiu, J. et al. Incidence of Guillain-Barré syndrome and ganglioside intake in Alcoi, Spain. Neuroepidemiology 12, 58-60 (1993).
31. Geisler, F. H., Dorsey, F. C. & Coleman, W. P. Recovery of motor function after spinal-cord injury-a randomized, placebo-controlled trial with GM-1 ganglioside. N. Engl. J. Med. 324, 1829-1838 (1991).
32. Wiederholt, W., Mulder, D. & Lambert, E. The Landry-Guillain-Barre-Strohl syndrome or polyradiculoneuropathy: historical review, report on 97 patients, and present concepts. Mayo Clin. Proc. 39, 427-451 (1964).
33. Sumner, A. J., Saida, K., Saida, T., Silberberg, D. H. & Asbury, A. K. Acute conduction block associated with experimental antiserum-mediated demyelination of peripheral nerve. Ann. Neurol. 11, 469-477 (1982).
34. Lafontaine, S., Rasminsky, M., Saida, T. & Sumner, A. J. Conduction block in rat myelinated fibres following acute exposure to anti-galactocerebroside serum. J. Physiol. 323, 287-306 (1982).
35. Saida, T. et al. In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome. Ann. Neurol. 11, 69-75 (1982).
36. Albers, J. W., Donofrio, P. D. & McGonagle, T. K. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 8, 528-539 (1985).
37. McLeod, J. G. Electrophysiological studies in the Guillain-Barré syndrome. Ann. Neurol. 9 (Suppl.), 20-27 (1981).
38. Uncini, A. & Kuwabara, S. Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update. Clin. Neurophysiol. 123, 1487-1495 (2012).
39. Feasby, T. E. et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 109, 1115-1126 (1986).
40. Feasby, T. E. et al. Acute "axonal" Guillain-Barré polyneuropathy. Neurology 37, 357 (1987).
41. Yuki, N., Yoshino, H., Sato, S. & Miyatake, T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40, 1900-1902 (1990).
42. Hafer-Macko, C. et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 40, 635-644 (1996).
43. McKhann, G. M. et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 338, 593-597 (1991).
44. Griffin, J. W. et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J. Neurocytol. 25, 33-51 (1996).
45. Hafer-Macko, C. E. et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 39, 625-635 (1996).
46. Ho, T. W., McKhann, G. M. & Griffin, J. W. Human autoimmune neuropathies. Annu. Rev. Neurosci. 21, 187-226 (1998).
47. Campbell, A. The aetiology of polyneuritis. Proc. R. Soc. Med. 51, 157-159 (1958).
48. Rhodes, K. M. & Tattersfield, A. E. Guillain-Barré syndrome associated with Campylobacter infection. Br. Med. J. (Clin. Res. Ed.) 285, 173-174 (1982).
49. Kaldor, J. & Speed, B. R. Guillain-Barré syndrome and Campylobacter jejuni: a serological study. Br. Med. J. (Clin. Res. Ed.) 288, 1867-1870 (1984).
50. Rees, J. H., Soudain, S. E., Gregson, N. A. & Hughes, R. A. Campylobacter jejuni infection and Guillain-Barré syndrome. N. Engl. J. Med. 333, 1374-1379 (1995).
51. Yuki, N. et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med. 178, 1771-1775 (1993).
52. Yuki, N. et al. Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann. Neurol. 36, 791-793 (1994).
53. Yuki, N. et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc. Natl Acad. Sci. USA 101, 11404-11409 (2004).
54. Ilyas, A. A. et al. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann. Neurol. 23, 440-447 (1988).
55. Gregson, N. A., Jones, D., Thomas, P. K. & Willison, H. J. Acute motor neuropathy with antibodies to GM1 ganglioside. J. Neurol. 238, 447-451 (1991).
56. Ho, T. W. et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann. Neurol. 45, 168-173 (1999).
57. O'Leary, C. P. et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J. Neurol. Neurosurg. Psychiatry 61, 649-651 (1996).
58. Chiba, A., Kusunoki, S., Shimizu, T. & Kanazawa, I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol. 31, 677-679 (1992).
59. Kaida, K. et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann. Neurol. 56, 567-571 (2004).
60. Pestronk, A., Choksi, R., Blume, G. & Lopate, G. Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone. Neurology 48, 1104-1106 (1997).
61. Rinaldi, S. et al. Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome. PLoS ONE 8, e82337 (2013).
62. Rinaldi, S., Brennan, K. M. & Willison, H. J. Heteromeric glycolipid complexes as modulators of autoantibody and lectin binding. Prog. Lipid Res. 49, 87-95 (2010).
63. Rinaldi, S., Brennan, K. M. & Willison, H. J. Combinatorial glycoarray. Methods Mol. Biol. 808, 413-423 (2012).
64. Willison, H. J. et al. Mechanisms of action of anti-GM1 and anti-GQ1b ganglioside antibodies in Guillain-Barré syndrome. J. Infect. Dis. 176 (Suppl. 2), S144-S149 (1997).
65. Greenshields, K. N. et al. The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. J. Clin. Invest. 11 9, 595-610 (2009).
66. Chiba, A., Kusunoki, S., Obata, H., Machinami, R. & Kanazawa, I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 43, 1911-1917 (1993).
67. Goodfellow, J. A. et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J. Neurosci. 25, 1620-1628 (2005).
68. McGonigal, R. et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 133, 1944-1960 (2010).
69. Susuki, K. et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci. 27, 3956-3967 (2007).
70. Halstead, S. K. et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain 127, 2109-2123 (2004).
71. O'Hanlon, G. M. et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124, 893-906 (2001).
72. Halstead, S. K. et al. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann. Neurol. 58, 203-210 (2005).
73. McGonigal, R. et al. C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. Acta Neuropathol. Commun. 4, 23 (2016).
74. Kusunoki, S., Shiina, M. & Kanazawa, I. Anti-Gal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 57, 736-738 (2001).
75. Cao-Lormeau, V. M. et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387, 1531-1539 (2016).
76. Araujo, L. M., Ferreira, M. L. & Nascimento, O. J. Guillain-Barré syndrome associated with the Zika virus outbreak in Brazil. Arq. Neuropsiquiatr. 74, 253-255 (2016).
77. White, M. K., Wollebo, H. S., David Beckham, J., Tyler, K. L. & Khalili, K. Zika virus: an emergent neuropathological agent. Ann. Neurol. 80, 479-489 (2016).
78. Parra, B. et al. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N. Engl. J. Med. 375, 1513-1523 (2016).
79. Greenwood, R. J. et al. Controlled trial of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 1, 877-879 (1984).
80. Osterman, P. O. et al. Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2, 1296-1299 (1984).
81. [No authors listed.] Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré syndrome Study Group. Neurology 35, 1096-1104 (1985).
82. [No authors listed.] Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann. Neurol. 22, 753-761 (1987).
83. van Doorn, P. A., Brand, A., Strengers, P. F., Meulstee, J. & Vermeulen, M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40, 209-212 (1990).
84. Kleyweg, R. P., van der Meché, F. G. & Meulstee, J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 38, 1639-1641 (1988).
85. Vermeulen, M., van der Meché, F. G., Speelman, J. D., Weber, A. & Busch, H. F. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J. Neurol. Sci. 70, 317-326 (1985).
86. van der Meché, F. G. & Schmitz, P. I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N. Engl. J. Med. 326, 1123-1129 (1992).
87. Hughes, R. A., Swan, A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 9, CD002063 (2014).
88. van den Berg, B., Bunschoten, C., van Doorn, P. A. & Jacobs, B. C. Mortality in Guillain-Barre syndrome. Neurology 80, 1650-1654 (2013).
89. [No authors listed.] Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 349, 225-230 (1997).
90. van Koningsveld, R. et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363, 192-196 (2004).
91. [No authors listed.] Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group. Lancet 341, 586-590 (1993).
92. Hughes, R. A. & van Doorn, P. A. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst. Rev. 8, CD001446 (2012).
93. Netherlands Trial Register. trialregister.nl http://www. trialregister.nl/trialreg/admin/rctview.asp?TC=2224 (2016)
94. Plomp, J. J. & Willison, H. J. Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J. Physiol. 587, 3979-3999 (2009).
95. Halstead, S. K. et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131, 1197-1208 (2008).
96. Fitzpatrick, A. M. et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J. Peripher. Nerv. Syst. 16, 84-91 (2011).
97. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02029378 (2014).
98. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02493725 (2016).